Ningbo Menovo Pharm Co Ltd Asset Resilience Ratio
Ningbo Menovo Pharm Co Ltd asset resilience ratio. Ningbo Menovo Pharm Co Ltd (603538) has an Asset Resilience Ratio of 3.47% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Ningbo Menovo Pharm Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ningbo Menovo Pharm Co Ltd (2011–2025)
Asset resilience ratio of Ningbo Menovo Pharm Co Ltd from 2011 to 2025. This chart shows how Ningbo Menovo Pharm Co Ltd's Asset Resilience Ratio has changed over time. See free cash flow generation of Ningbo Menovo Pharm Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Ningbo Menovo Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 603538 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥164.41 Million | 3.47% |
| Total Liquid Assets | CN¥164.41 Million | 3.47% |
Asset Resilience Insights
- Limited Liquidity: Ningbo Menovo Pharm Co Ltd maintains only 3.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ningbo Menovo Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ningbo Menovo Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Ningbo Menovo Pharm Co Ltd Asset Resilience Ratio by Year (2011–2025)
Ningbo Menovo Pharm Co Ltd asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Ningbo Menovo Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.47% | CN¥216.82 Million ≈ $31.73 Million |
CN¥4.85 Billion ≈ $710.06 Million |
+1.15pp |
| 2024-12-31 | 3.32% | CN¥154.44 Million ≈ $22.60 Million |
CN¥4.65 Billion ≈ $680.62 Million |
-2.75pp |
| 2023-12-31 | 6.07% | CN¥268.65 Million ≈ $39.31 Million |
CN¥4.42 Billion ≈ $647.30 Million |
+1.15pp |
| 2022-12-31 | 4.92% | CN¥217.38 Million ≈ $31.81 Million |
CN¥4.42 Billion ≈ $646.71 Million |
-4.36pp |
| 2021-12-31 | 9.28% | CN¥371.38 Million ≈ $54.34 Million |
CN¥4.00 Billion ≈ $585.54 Million |
+4.93pp |
| 2020-12-31 | 4.35% | CN¥133.14 Million ≈ $19.48 Million |
CN¥3.06 Billion ≈ $448.17 Million |
+0.50pp |
| 2019-12-31 | 3.85% | CN¥100.60 Million ≈ $14.72 Million |
CN¥2.61 Billion ≈ $382.51 Million |
-12.80pp |
| 2017-12-31 | 16.65% | CN¥252.00 Million ≈ $36.88 Million |
CN¥1.51 Billion ≈ $221.50 Million |
+16.61pp |
| 2012-12-31 | 0.04% | CN¥350.50K ≈ $51.29K |
CN¥831.58 Million ≈ $121.69 Million |
-0.43pp |
| 2011-12-31 | 0.48% | CN¥3.37 Million ≈ $493.82K |
CN¥709.97 Million ≈ $103.89 Million |
-- |
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more